C2N Diagnostics Suffers Data Breach Exposing Sensitive Patient Information
C2N Diagnostics, a St. Louis-based biotechnology company specializing in Alzheimer’s and neurodegenerative disorder blood tests, confirmed a cyberattack on March 6, 2026, that compromised sensitive personal data. The breach involved unauthorized access to employee email accounts containing patient information.
Exposed Data Included:
- Names
- Dates of birth
- Contact details
- Health insurance information
- Blood test results and other health data
- Social Security numbers
The company clarified that financial information, such as credit card numbers or bank details, was not affected. After containing the attack, C2N launched an investigation and reported the incident to the U.S. Department of Health and Human Services (HHS) on April 27, 2026. A total of 2,027 individuals in the U.S. were impacted.
C2N Diagnostics, founded in 2007, operates a clinical laboratory in St. Louis and collaborates with research institutions and pharmaceutical companies globally. The law firm Shamis & Gentile P.A. is investigating potential legal action for affected individuals, who may be eligible for compensation.
Source: https://www.claimdepot.com/investigations/c2n-diagnostics-data-breach-2026
C2N Diagnostics cybersecurity rating report: https://www.rankiteo.com/company/c2n-diagnostics
"id": "C2N1780698498",
"linkid": "c2n-diagnostics",
"type": "Breach",
"date": "3/2026",
"severity": "85",
"impact": "4",
"explanation": "Attack with significant impact with customers data leaks"{'affected_entities': [{'customers_affected': '2027',
'industry': 'Healthcare / Biotechnology',
'location': 'St. Louis, USA',
'name': 'C2N Diagnostics',
'type': 'Biotechnology Company'}],
'attack_vector': 'Unauthorized access to employee email accounts',
'data_breach': {'number_of_records_exposed': '2027',
'personally_identifiable_information': 'Yes',
'sensitivity_of_data': 'High',
'type_of_data_compromised': ['Names',
'Dates of birth',
'Contact details',
'Health insurance information',
'Blood test results',
'Health data',
'Social Security numbers']},
'date_detected': '2026-03-06',
'description': 'C2N Diagnostics, a St. Louis-based biotechnology company '
'specializing in Alzheimer’s and neurodegenerative disorder '
'blood tests, confirmed a cyberattack on March 6, 2026, that '
'compromised sensitive personal data. The breach involved '
'unauthorized access to employee email accounts containing '
'patient information.',
'impact': {'data_compromised': 'Sensitive personal and health information',
'identity_theft_risk': 'High',
'legal_liabilities': 'Potential legal action',
'payment_information_risk': 'None',
'systems_affected': 'Employee email accounts'},
'investigation_status': 'Ongoing',
'references': [{'source': 'Incident disclosure'}],
'regulatory_compliance': {'legal_actions': 'Potential legal action by Shamis '
'& Gentile P.A.',
'regulatory_notifications': ['U.S. Department of '
'Health and Human '
'Services (HHS) on '
'April 27, 2026']},
'response': {'containment_measures': 'Contained the attack'},
'title': 'C2N Diagnostics Suffers Data Breach Exposing Sensitive Patient '
'Information',
'type': 'Data Breach'}